Ana Clara Carrera

Prof. Ana Clara Carrera

Department of Immunology and Oncology, National Center for Biotechnology, Scientific Research Council (CNB-CSIC), Autonomous University of Madrid, Cantoblanco, Madrid; E-28049, Spain
orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2005 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
DBDomingo F. Barber
Domingo F. Barber
ABAlmira Bartolomé
Almira Bartolomé
CHCarmen Hernandez
Carmen Hernandez
JFJuana M Flores
Juana M Flores
CRClara Redondo
Clara Redondo
Ana Clara CarreraAna Clara Carrera
Ana Clara Carrera

18 October 2001 in Nature
Verified
Journal Article
Closed access
BABeatriz Alvarez
Beatriz Alvarez
CMCarlos Martínez-A.
Carlos Martínez-A.
BBBoudewijn M. T. Burgering
Boudewijn M. T. Burgering
Ana Clara CarreraAna Clara Carrera
Ana Clara Carrera

16 October 2000 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
CJConcepción Jiménez
Concepción Jiménez
RPRosario Armas Portela
Rosario Armas Portela
MMMario Mellado
Mario Mellado
JRJose Miguel Rodríguez-Frade
Jose Miguel Rodríguez-Frade
JCJohn Collard
John Collard
Ana Clara CarreraAna Clara Carrera
Ana Clara Carrera
Cell migration represents an important cellular response that utilizes cytoskeletal reorganization as its driving force. Here, we describe a new signaling cascade linking PDGF receptor stimulation to actin rearrangements and cell migration. We demonstrate that PDGF activates Cdc42 and its downstream effector N-WASP to mediate filopodia formation, actin stress fiber disassembly, and a reduction in focal adhesion complexes. Induction of the Cdc42 pathway is independent of phosphoinositide 3-kinase (PI3K) enzymatic activity, but it is dependent on the p85α regulatory subunit of PI3K. Finally, data are provided showing that activation of this pathway is required for PDGF-induced cell migration on collagen. These observations show the essential role of the PI3K regulatory subunit p85α in controlling PDGF receptor–induced cytoskeletal changes and cell migration, illustrating a novel signaling pathway that links receptor stimulation at the cell membrane with actin dynamics.

15 January 1993 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
Ana Clara CarreraAna Clara Carrera
Ana Clara Carrera
KAK Alexandrov
K Alexandrov
TRT M Roberts
T M Roberts
The study of the various protein kinases reveals that, despite their considerably diversity, they have evolved from a common origin. Eleven conserved subdomains have been described that encompass the catalytic core of these enzymes. One of these conserved regions, subdomain II, contains an invariant lysine residue present in all known protein kinase catalytic domains. Two facts have suggested that this conserved lysine of subdomain II is essential for binding ATP: (i) several investigators have demonstrated that this residue is physically proximal to the ATP molecule, and (ii) conservative substitutions at this site render the kinase inactive. However, these results are also consistent with a functional role of the conserved lysine of subdomain II in orienting or facilitating the transfer of phosphate. To study in more detail the role of subdomain II, we have generated mutants of the protein-tyrosine kinase pp56lck that have single amino acid substitutions within the area surrounding the conserved residue Lys-273 in subdomain II. When compared with wild-type pp56lck, these mutants displayed profound reductions in their phosphotransfer efficiencies and small differences in their affinities for ATP. Further, the substitution of arginine for Lys-273 resulted in a mutant protein unable to transfer the gamma-phosphate of ATP but able to bind 8-azido-ATP with an efficiency similar to that of wild-type pp56lck. These results suggest that the region including Lys-273 of subdomain II is involved in the enzymatic process of phosphate transfer, rather than in anchoring ATP.

1 September 2004 in Immunity
Verified
Journal Article
Closed access
CNCésar Nombela-Arrieta
César Nombela-Arrieta
RLRosa Ana Lacalle
Rosa Ana Lacalle
MMMarı́a C. Montoya
Marı́a C. Montoya
YKYuya Kunisaki
Yuya Kunisaki
DMDiego Megias
Diego Megias
JSJens Stein
Jens Stein

1 February 1998 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
CJConcepción Jimenez
Concepción Jimenez
DJDavid R. Jones
David R. Jones
PRPablo Rodríguez‐Viciana
Pablo Rodríguez‐Viciana
AGAna González-García
Ana González-García
ELEsther Leonardo
Esther Leonardo
Ana Clara CarreraAna Clara Carrera
Ana Clara Carrera
P85/p110 phosphoinositide 3‐kinase (PI3K) is a heterodimer composed of a p85‐regulatory and a p110‐catalytic subunit, which is involved in a variety of cellular responses including cytoskeletal organization, cell survival and proliferation. We describe here the cloning and characterization of p65‐PI3K, a mutant of the regulatory subunit of PI3K, which includes the initial 571 residues of the wild type p85α‐protein linked to a region conserved in the eph tyrosine kinase receptor family. We demonstrate that this mutation, obtained from a transformed cell, unlike previously engineered mutations of the regulatory subunit, induces the constitutive activation of PI3K and contributes to cellular transformation. This report links the PI3K enzyme to mammalian tumor development for the first time.